Topic Highlight
Copyright ©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Oct 14, 2015; 21(38): 10760-10775
Published online Oct 14, 2015. doi: 10.3748/wjg.v21.i38.10760
Impact of new treatment options for hepatitis C virus infection in liver transplantation
Elda Righi, Angela Londero, Alessia Carnelutti, Umberto Baccarani, Matteo Bassetti
Elda Righi, Angela Londero, Alessia Carnelutti, Matteo Bassetti, Infectious Diseases Division, Santa Maria della Misericordia University Hospital, 33100 Udine, Italy
Umberto Baccarani, Liver Transplant Unit, Santa Maria della Misericordia University Hospital, 33100 Udine, Italy
Author contributions: Righi E analyzed the literature and wrote the manuscript; Baccarani U, Carnelutti A, Londero A and Bassetti M reviewed the literature.
Conflict-of-interest statement: The authors have no conflict of interest to report.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Elda Righi, MD, PhD, Infectious Diseases Division, Santa Maria della Misericordia University Hospital, 50 Colugna Street, 33100 Udine, Italy. elda.righi@libero.it
Telephone: +39-0432-559355 Fax: +39-0432-559360
Received: April 30, 2015
Peer-review started: May 7, 2015
First decision: June 23, 2015
Revised: July 12, 2015
Accepted: September 15, 2015
Article in press: September 15, 2015
Published online: October 14, 2015
Processing time: 166 Days and 22.2 Hours
Core Tip

Core tip: Until recently, a well-tolerated and effective treatment protocol to address the recurrence of hepatitis C virus (HCV) infection following liver transplantation has been an important unmet clinical need. Safe and effective treatment options are now available thanks to the approval of new classes of direct antiviral agents. The aim of this review was to summarize the outcome of previous treatments and discuss the impact of current options for the treatment of HCV among liver transplantation candidates and recipients, including coinfected human immunodeficiency virus/HCV patients.